PUBLISHER: The Business Research Company | PRODUCT CODE: 1270631
PUBLISHER: The Business Research Company | PRODUCT CODE: 1270631
“Prenatal DNA Sequencing Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on prenatal dna sequencing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for prenatal dna sequencing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The prenatal dna sequencing market global report ” from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Major players in the prenatal dna sequencing market are Agilent Technologies Inc., BGI Group, F. Hoffmann-La Roche, Illumina Inc., Laboratory Corporation of America Holdings, Natera Inc., Genomic Health Inc., Myriad Genetics Inc., Invitae Corporation, PerkinElmer Inc., Macrogen Inc., Pacific Biosciences, Genewiz LLC, 10x Genomics Inc., Oxford Nanopore Technologies Limited, and Thermo Fisher Scientific Inc.
The global prenatal DNA sequencing market is expected to grow from $1.84 billion in 2022 to $2.09 billion in 2023 at a compound annual growth rate (CAGR) of 13.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The prenatal DNA sequencing market is expected to grow to $3.52 billion in 2027 at a CAGR of 13.9%.
The prenatal DNA sequencing market includes revenues earned by entities by providing services such as prenatal next-generation sequencing, whole genome sequencing, DNA extraction, DNA fragmentation, and data collection and sequence analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
Prenatal DNA sequencing refers to a method of sequencing the DNA of an unborn baby by using the blood sample from the mother that helps to reveal the full genetic code of the unborn baby. It is used to detect fetal disorders or diseases.
North America was the largest region in the prenatal DNA sequencing market in 2022. The regions covered in the prenatal DNA sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The main types of prenatal DNA sequencing are genetic diseases and nonhereditary diseases. Genetic diseases refer to any disorder or disease that is caused by mutations in one or more genes. DNA sequencing helps to determine whether a gene contains a mutation that causes a disorder. It is used in various applications such as hemophilia, down syndrome, cystic fibrosis, autism, DiGeorge syndrome, AIDS, cancer, and others by academic research, clinical research, hospitals and clinics, pharmaceutical and biotechnology companies, and other users.
The increasing prevalence of cancer is expected to propel the growth of the prenatal DNA sequencing market going forward. Cancer refers to a disease in which a few body cells grow uncontrollably and spread to other parts. Prenatal DNA sequencing in cancer is used to detect fetal aneuploidy in maternal plasma and to identify cancer in the fetus. The sequencing reveals the inherited or germline DNA changes that raise a person's chance of developing cancer. For instance, according to Globocan, a Switzerland-based provider of a worldwide database of cancer incidence and mortality rates, in 2020, there were around 19.29 million new cancer cases, and the number of cancer cases in a 5-year span is estimated to be 50.55 million. Therefore, the prevalence of cancer is driving the prenatal DNA sequencing market.
Product innovation is a key trend gaining popularity in the prenatal DNA sequencing market. Major companies operating in the market are focused on developing innovative solutions to strengthen their market position. For instance, in November 2022, Juno Diagnostics, Inc., a US-based health technology company that democratizes access to valuable genetic information, launched the noninvasive prenatal screening test "Hazel". The test is uniquely designed with no risk of miscarriage, and it can be performed as early as 9 weeks into pregnancy by using a small amount of blood. It screens the pregnancy for common genetic conditions caused by extra or missing chromosomes, such as Down syndrome, Edwards syndrome, and Patau syndrome.
In November 2022, Myriad Genetics, Inc., a US-based provider of genetic testing and precision medicine acquired Gateway Genomics, LLC for an undisclosed amount. Myriad expects to expand and strengthen its portfolio of women's health products, as well as provide access to personalized genetic tests, with the combined resources of this acquisition. Gateway Genomics, LLC is a US-based personal genomics, and prenatal DNA company and a developer of consumer genetic tests.
The countries covered in the prenatal DNA sequencing market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The prenatal DNA sequencing market research report is one of a series of new reports from The Business Research Company that provides prenatal DNA sequencing market statistics, including the prenatal DNA sequencing industry global market size, regional shares, competitors with a prenatal DNA sequencing market share, detailed prenatal DNA sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the prenatal DNA sequencing industry. This prenatal DNA sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.